Literature DB >> 488133

Pharmacokinetic parameters of 14C oxithiopurinol in rat.

C Pasquier, C Auscher.   

Abstract

The study with labelled compound has shown that in rat, as in man, thiopurinol is primarily and rapidly converted into oxithiopurinol. More than 80% of the radioactivity of plasma was identified as oxithiopurinol less than 10 minutes after intravenous or oral administration. The parameters of oxithiopurinol were estimated from the decline of radioactivity in blood from 5 minutes to 8 hours after intravenous administration of 4 microCi/100 g of thiopurinol (8 animals) or oxithiopurinol (5 animals). Half lives of oxithiopurinol t 1/2 (beta) were 2.52 +/- 0.78 hr and 2.90 +/- 1.00 hr and clearance 2.00 +/- 0.36 ml/min. and 3.38 +/- 0.69 respectively. Estimate of renal clearance for oxithiopurinol in rat was 4,17 ml/min. The rapidity of hydroxylation and of elimination of oxithiopurinol might be assumed to be the cause of the apparent ineffectiveness of thiopurinol in vivo on xanthine oxidase activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 488133     DOI: 10.1007/BF03189402

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  13 in total

1.  Clearance of allantoin in the rat and dog as a measure of glomerular filtration rates.

Authors:  M FRIEDMAN; S O BYERS
Journal:  Am J Physiol       Date:  1947-11-01

2.  [Uric acid inhibitors in the treatment of gout. Apropos of 126 cases].

Authors:  H Serre; L Simon; J Claustre
Journal:  Sem Hop       Date:  1970-12-08

3.  Thiopurinol and purine metabolism. Metabolic and radioisotope studies.

Authors:  H A Simmonds; A Cadenhead; J S Cameron; T J Rising; R Grahame; B M Dean
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

4.  [Molecular bases of the treatment of Lesch-Nyhan syndrome, related syndromes and common gout].

Authors:  F Delbarre; C Auscher; A de Gery
Journal:  Biochimie       Date:  1972       Impact factor: 4.079

5.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

6.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.

Authors:  G B Elion; A Kovensky; G H Hitchings
Journal:  Biochem Pharmacol       Date:  1966-07       Impact factor: 5.858

7.  [Methods of isolation and determination of urinary 4-thio-6-hydroxypyrazolo(3,4 d)pyrimidine in patients treated with thiopurinol].

Authors:  C Pasquier; C Auscher; P Pehuet; F Delbarre
Journal:  Ann Biol Clin (Paris)       Date:  1975       Impact factor: 0.459

8.  [Inactivation by 4,6 disubstituted pyrazolo (3,4-d) pyrimidines of the arsenolysis of guanosine by erythrocyte purine nucleoside phosphorylase].

Authors:  K V Thang; F Delbarre; C Auscher; L Gerbaut
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1977-02-07

9.  Secretion of inorganic phosphate in the rat nephron.

Authors:  J F Boundry; U Troehler; M Touabi; H Fleisch; J P Bonjour
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

10.  Allopurinol kinetics.

Authors:  K Hande; E Reed; B Chabner
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.